Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Abstract

Background:

Changes in gray matter (GM) volume may be a useful measure of tissue loss in multiple sclerosis (MS).

Objectives:

To investigate the rate, patterns, and disability correlates of GM volume change in an MS treatment clinical trial.

Methods:

Patients (n=140) with relapsing−remitting MS were randomized to intramuscular (IM) interferon (IFN) beta-1a or placebo. Treatment effects on GM fraction (GMF) and white matter (WM) fraction (WMF) changes, differences in rates of GMF and WMF change in year one and two on treatment, and differences in atrophy rates by disease progression status were assessed retrospectively.

Results:

Significantly less GM atrophy (during year two), but not WM atrophy (at any point), was observed with IM IFN beta-1a compared with placebo. Pseudoatrophy effects were more apparent in WM than in GM; in year one, greater WM volume loss was observed with IM IFN beta-1a than with placebo, whereas GM volume loss was similar between groups. Risk of sustained disability progression was significantly associated with GM, but not WM, atrophy.

Conclusions:

These results suggest that GMF change is more meaningful than WMF as a marker of tissue loss and may be useful to augment whole brain atrophy measurements in MS clinical trials.

Keywords

Brain atrophy brain volume gray matter atrophy gray matter fraction intramuscular interferon beta-1a magnetic resonance imaging multiple sclerosis

Get full access to this article

View all access options for this article.

References

Chard

Griffin

Rashid

. Progressive grey matter atrophy in clinically early relapsing–remitting multiple sclerosis. Mult Scler 2004; 10: 387–391.

Dalton

Miszkiel

Barker

. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251: 407–413.

Fisher

Lee

Nakamura

Rudick

. Gray matter atrophy in multiple sclerosis: A longitudinal study. Ann Neurol 2008; 64: 255–265.

Tedeschi

Lavorgna

Russo

. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005; 65: 280–285.

Tiberio

Chard

Altmann

. Gray and white matter volume changes in early RRMS: A 2-year longitudinal study. Neurology 2005; 64: 1001–1007.

Bø

Vedeler

Nyland

Trapp

Mørk

. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003; 62: 723–732.

Kutzelnigg

Lassmann

. Cortical lesions and brain atrophy in MS. J Neurol Sci 2005; 233: 55–59.

Geurts

Bö

Pouwels

. Cortical lesions in multiple sclerosis: Combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol 2005; 26: 572–577.

Ginsberg

Martin

. Ultrastructural analysis of the progression of neurodegeneration in the septum following fimbria-fornix transection. Neuroscience 1998; 86: 1259–1272.

10.

Liu

Gross

Wheatley

. The acute phase of Wallerian degeneration: Longitudinal diffusion tensor imaging of the fornix following temporal lobe surgery. Neuroimage 2013; 74: 128–139.

11.

Pomeroy

Jordan

Frank

. Focal and diffuse cortical degenerative changes in a marmoset model of multiple sclerosis. Mult Scler 2010; 16: 537–548.

12.

Rocca

Mesaros

Preziosa

. Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: A diffusion tensor MRI study. Mult Scler 2013; 19: 1610–1617.

13.

Filippi

. MRI measures of neurodegeneration in multiple sclerosis: Implications for disability, disease monitoring, and treatment. J Neurol 2015 Jan; 262(1): 1–6.

14.

Filippi

Preziosa

Rocca

. Magnetic resonance outcome measures in multiple sclerosis trials: Time to rethink? Curr Opin Neurol 2014; 27: 290–299.

15.

De Stefano

Airas

Grigoriadis

. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs 2014; 28: 147–156.

16.

Rudick

Fisher

Lee

. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698–1704.

17.

Zivadinov

Locatelli

Cookfair

. Interferon beta-1a slows progression of brain atrophy in relapsing–remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler 2007; 13: 490–501.

18.

Nakamura

Fisher

. Segmentation of brain magnetic resonance images for measurement of gray matter atrophy in multiple sclerosis patients. Neuroimage 2009; 44: 769–776.

19.

Horakova

Cox

Havrdova

. Evolution of different MRI measures in patients with active relapsing–remitting multiple sclerosis over 2 and 5 years: A case-control study. J Neurol Neurosurg Psychiatry 2008; 79: 407–414.

20.

Vercellino

Masera

Lorenzatti

. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol 2009; 68: 489–502.

21.

Jacobs

Cookfair

Rudick

. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [published correction appears in Ann Neurol 1996; 40(3): 480]. Ann Neurol 1996; 39: 285–294.

22.

Simon

Jacobs

Campion

. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43: 79–87.

23.

Sled

Zijdenbos

Evans

. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87–97.

24.

Zhou

Bai

. Atlas-based fuzzy connectedness segmentation and intensity nonuniformity correction applied to brain MRI. IEEE Trans Biomed Eng 2007; 54: 122–129.

25.

Chen

Pike

. Origins of the BOLD post-stimulus undershoot. Neuroimage 2009; 46: 559–568.

26.

Bendfeldt

Egger

Nichols

. Effect of immunomodulatory medication on regional gray matter loss in relapsing–remitting multiple sclerosis − a longitudinal MRI study. Brain Res 2010; 1325: 174–182.

27.

Calabrese

Bernardi

Atzori

. Effect of disease-modifying drugs on cortical lesions and atrophy in relapsing–remitting multiple sclerosis. Mult Scler 2012; 18: 418–424.

28.

Kapoor

Furby

Hayton

. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: A randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681–688.

29.

Filippi

Rocca

Pagani

. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2014; 85: 851–858.

30.

Nakamura

Vollmer

Gorfine

. Effect of laquinimod on gray matter and white matter atrophy in relapsing–remitting multiple sclerosis: Analysis of the BRAVO phase III trial [abstract P041]. Mult Scler 2014; 20: 84–85.

31.

Vidal-Jordana

Sastre-Garriga

Perez-Miralles

. Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Mult Scler 2013; 19: 1175–1181.

32.

Richert

Zierak

Bash

. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b. Mult Scler 2000; 6: 86–90.

33.

Amato

Portaccio

Goretti

. Association of neocortical volume changes with cognitive deterioration in relapsing–remitting multiple sclerosis. Arch Neurol 2007; 64: 1157–1161.

34.

Fisniku

Chard

Jackson

. Gray matter atrophy is related to long-term disability in multiple sclerosis [published correction appears in Ann Neurol 2009; 65(2): 232]. Ann Neurol 2008; 64: 247–254.

35.

Horakova

Dwyer

Havrdova

. Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis: A 5-year longitudinal study. J Neurol Sci 2009; 282: 112–119.

36.

Rudick

Trapp

. Gray-matter injury in multiple sclerosis. N Engl J Med 2009; 361: 1505–1506.

37.

Sanfilipo

Benedict

Sharma

. The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005; 26: 1068–1077.

38.

Fisher

Cothren

Tkach

. Knowledge-based 3D segmentation of the brain in MR images for quantitative multiple sclerosis lesion tracking. Proc SPIE 1997; 3034: 19–25.

39.

Bendfeldt

Klöppel

Nichols

. Multivariate pattern classification of gray matter pathology in multiple sclerosis. Neuroimage 2012; 60: 400–408.